How can life be made easier for people with epilepsy?

That was the question posed by Christer Sjögren, one of SWIPP’s two founders. Our story begins before 2017. After a successful career in the pharmaceutical industry, holding senior positions in several different companies, Christer decides to look for a new challenge. This turns out to be creating the best possible product for treating convulsive epilepsy seizures. The idea of the buccal film with midazolam is born, and soon thereafter he submits a patent application.

Bengt Westrin, the co-founder of SWIPP, has successfully developed and patented a medical oral film for another company. Christer Sjögren and Bengt Westrin are former colleagues, and decide to collaborate and pool their expertise. Bengt has extensive experience of pharmaceutical development and understands the necessary stages and conditions of a project.

In October 2017, SWIPP is founded. The company’s focus is the buccal midazolam film project, but it won’t be long before new ideas take shape. 

Current events

April 2022
April 2022
Maj 2022
Q3 2022
Q4 2022

The results of market research conducted by Drive Research (US) are released. Forty epilepsy specialists in the USA, the UK, Germany and France were asked about SWIPP’s buccal film (Project 1).
The responses showed unequivocally that they appreciated the product and that they would prescribe it if it were available. 

The results of the first study within Project 2 is released: SWIPP-011. These results are also very positive and confirm that the product concept in Project 2 works.

A new website is launched, introducing for the first time SWIPP to a wider audience. 

Preparing a pre-IND meeting with the FDA about SWIPP’s Project 2, including the results from SWIPP-011. 

New share issue planned for Q4 2022. 

Our history

2017

December 2017

Three seed investors who share SWIPP’s vision get on board: Lars Hedbys, Lars Persson, and Johan & Annette Säfholm. 

2017
2018

February 2018

Cooperation begins with the regulatory advisor SOFUS in Stockholm (now ProPharma Group). 

2018
2018

April 2018

Regulatory advice received from the Swedish Medical Products Agency (MPA/Läkemedelsverket) and from the MHRA in the UK. 

2018
2018

June 2018

Conducting 20 in-depth interviews with neurologists, parents and other caretakers in the epilepsy field. The product concept is well received. The pace picks up. 

2018
2018

September 2018

Cooperation begins with Quinta-Analytica in Prague, a one-stop-shop CRO specialized on Phase I studies and bioequivalence studies. 

2018
2018

October 2018

Cooperation begins with the GMP manufacturer AdhexPharma in France. AdhexPharma also decides to invest in SWIPP. 

2018
2019

February 2019

Scientific Advice Meeting with the Swedish MPA. 

2019
2019

May 2019

Advisory meeting with the Swedish Dental and Pharmaceutical Benefits Agency (TLV) regarding future pricing for SWIPP’s product. 

2019
2019

August 2019

SWIPP’s first patent application is approved in Europe (EPO).
2019
2020

April 2020

Mastan AB, AB Seglarevägen and Margaretha Cronvall are welcomed as new shareholders. 

2020
2020

December 2020

The first GMP batch of the buccal midazolam film is successfully manufactured – at the first attempt. This batch is then used in the first clinical study: SWIPP-010.
2020
2021

January 2021

Eight new co-owners are welcomed on board, including a number of successful entrepreneurs from the health care and biotech industries.

2021
2021

March 2021

The results of the SWIPP-010 study are released. These are deemed to be very positive by the Board and the management.
2021
2021

May 2021

A second Scientific Advice Meeting with the Swedish MPA, to discuss the results of SWIPP-010, the design of the next study (SWIPP-012), and other aspects of the company’s first project.
2021
2021

August 2021

SWIPP’s second patent application is submitted to the European Patent Office (EPO).
2021
2021

October 2021

A COO is employed, Sebastian Hansson.
2021
2021

November 2021

An unusually eventful month. A share issue is made, with 15 of the company’s 17 co-owners participating. Intensive preparations continue for SWIPP-012, and of SWIPP-011 which will be the first study within Project 2. Clinical trial applications submitted to the State Institute for Drug Control (SUKL) in the Czech Republic are approved, import and export licences are granted for the trial product, and a new GMP batch is manufactured. All deadlines are met! 

2021
2022

January 2022

The results of the SWIPP-012 study are released, ahead of schedule. These results are also deemed to be very positive. The path to product approval in Europe can now be mapped out.
2022